Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Cheng Liao

Lianshan Zhang

Jiahua Jiang

Piaoyang Sun

Xin Ye

Changyong Yang

Xiaohua Wu

Qing Yang

Xiaoxing Huang

Xueming Qian

Fei Teng

Quanren Wang

Jifang Gong

Dingwei Ye

Lin Shen

Zupeng Xu

Jing Gao

The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.

Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors

The present invention provides an anti-ox40 antibody, an antigen-binding fragment thereof, and the pharmaceutical use. Further, the present application provides a chimeric antibody and a humanized antibody, the chimeric antibody and the humanized antibody comprising a CDR region from the anti-OX40 antibody and the antigen-binding fragment thereof, and also provides a pharmaceutical composition comprising the anti-OX40 antibody and the antigen-binding fragment thereof, and the use thereof as a drug for treating cancers.

Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use

The present disclosure relates to a human IL-4R binding antibody, an antigen binding fragment thereof, and a medical use thereof. Provided are a chimeric antibody and a humanized antibody, including a CDR region from a human IL-4R binding antibody and an antigen binding fragment thereof, a pharmaceutical composition including the human IL-4R binding antibody and the antigen binding fragment thereof, and a use thereof as a drug treating allergic disease. Also provided is a use of the humanized antibody IL-4R binding antibody in preparing a drug used for treating IL-4R mediated diseases or illnesses.

Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof

A method for preventing or treating tumor diseases with a combination of a tyrosine kinase inhibitor and a CDK4/6 inhibitor is provided. In particular, a method for preventing or treating tumor diseases, including administering to a patient a tyrosine kinase inhibitor of a compound of formula (I), or a complex, a pharmaceutically acceptable salt or a stereoisomer thereof and a CDK4/6 inhibitor is provided. 

Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor

Growing community of inventors

Jiangsu, China

Cheng Liao